LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1. - Dataset (ID:20240)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-231 | A443654 | 1.11 | uM | LJP6 | 72 | hr | 868 | 633 | 3486 | 0.1816 | -0.0898 |
| MDA-MB-231 | OSI-027 | 1.11 | uM | LJP6 | 72 | hr | 868 | 2527 | 3486 | 0.7249 | 0.6337 |
| MDA-MB-231 | XMD11-85h | 1.11 | uM | LJP6 | 72 | hr | 868 | 2718 | 3486 | 0.7798 | 0.7068 |
| MDA-MB-231 | HG-6-64-01 | 1.11 | uM | LJP6 | 72 | hr | 868 | 1682 | 3486 | 0.4826 | 0.3111 |
| MDA-MB-231 | WH-4-025 | 1.11 | uM | LJP5 | 72 | hr | 868 | 770 | 3486 | 0.2211 | -0.0372 |
| MDA-MB-231 | WZ-4-145 | 1.11 | uM | LJP6 | 72 | hr | 868 | 2672 | 3486 | 0.7666 | 0.6892 |
| MDA-MB-231 | XMD16-144 | 1.11 | uM | LJP5 | 72 | hr | 868 | 1310 | 3486 | 0.3758 | 0.1689 |
| MDA-MB-231 | Brivanib | 1.11 | uM | LJP5 | 72 | hr | 868 | 2996 | 3486 | 0.8595 | 0.8130 |
| MDA-MB-231 | Buparlisib | 1.11 | uM | LJP5 | 72 | hr | 868 | 1779 | 3486 | 0.5105 | 0.3482 |
| MDA-MB-231 | BX-912 | 1.11 | uM | LJP5 | 72 | hr | 868 | 1867 | 3486 | 0.5356 | 0.3816 |
| MDA-MB-231 | Canertinib | 1.11 | uM | LJP6 | 72 | hr | 868 | 2820 | 3486 | 0.8090 | 0.7456 |
| MDA-MB-231 | Celastrol | 1.11 | uM | LJP6 | 72 | hr | 868 | 877 | 3486 | 0.2516 | 0.0034 |
| MDA-MB-231 | CGP60474 | 1.11 | uM | LJP5 | 72 | hr | 868 | 662 | 3486 | 0.1901 | -0.0785 |
| MDA-MB-231 | CGP60474 | 1.11 | uM | LJP6 | 72 | hr | 868 | 621 | 3486 | 0.1782 | -0.0943 |
| MDA-MB-231 | CHIR-99021 | 1.11 | uM | LJP6 | 72 | hr | 868 | 2901 | 3486 | 0.8321 | 0.7764 |
| MDA-MB-231 | CP724714 | 1.11 | uM | LJP5 | 72 | hr | 868 | 2825 | 3486 | 0.8103 | 0.7474 |
| MDA-MB-231 | CP466722 | 1.11 | uM | LJP5 | 72 | hr | 868 | 3252 | 3486 | 0.9328 | 0.9105 |
| MDA-MB-231 | Crizotinib | 1.11 | uM | LJP5 | 72 | hr | 868 | 1788 | 3486 | 0.5130 | 0.3515 |
| MDA-MB-231 | Momelotinib | 1.11 | uM | LJP5 | 72 | hr | 868 | 2273 | 3486 | 0.6520 | 0.5366 |
| MDA-MB-231 | Dasatinib | 1.11 | uM | LJP5 | 72 | hr | 868 | 497 | 3486 | 0.1427 | -0.1416 |
| MDA-MB-231 | Dasatinib | 1.11 | uM | LJP6 | 72 | hr | 868 | 508 | 3486 | 0.1457 | -0.1375 |
| MDA-MB-231 | Dovitinib | 1.11 | uM | LJP5 | 72 | hr | 868 | 1755 | 3486 | 0.5035 | 0.3389 |
| MDA-MB-231 | Enzastaurin | 1.11 | uM | LJP5 | 72 | hr | 868 | 3538 | 3486 | 1.0149 | 1.0198 |
| MDA-MB-231 | Erlotinib | 1.11 | uM | LJP5 | 72 | hr | 868 | 3338 | 3486 | 0.9576 | 0.9436 |
| MDA-MB-231 | Foretinib | 1.11 | uM | LJP5 | 72 | hr | 868 | 1337 | 3486 | 0.3835 | 0.1791 |